Report shows Big Pharma's patent cliff in graphic detail

The Economist's analysis of Big Pharma's patent cliff woes is worth looking at if only for the accompanying graph and its plunging sales lines for Pfizer's ($PFE) Lipitor, Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix, Novartis' ($NVS) Diovan and Merck's ($MRK) Singulair. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.